Dermagraft Overview
Dermagraft® is a cryopreserved human fibroblast-derived dermal substitute, approved by the FDA for the treatment of diabetic foot ulcers.
Dermagraft provides a combination of living fibroblasts, matrix proteins, and bound factors that protect the wound and stimulate dynamic events that promote regeneration and repair.
With over 200,000 applications to date, Dermagraft has become an integral part of the standard of care for diabetic foot ulcers and has enabled clinical professionals to make a profound difference in the lives of thousands of patients with diabetes.
Visit Dermagraft.com to view Case Studies, Educational Videos and learn more about why thousands of wound care specialists have made the shift to Dermagraft for faster healing times with clinically proven results.1
Reference
- Marston et al. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care. 2003;26(6):1701-1705.
Important Safety Information about Dermagraft®
Dermagraft is indicated for use in the treatment of full-thickness diabetic foot ulcers greater than 6 weeks duration, which extend through the dermis, but without tendon, muscle, joint capsule, or bone exposure. Refer to Dermagraft Directions for Use for more information. Results may vary and not all patients will achieve complete wound closure with Dermagraft. In the pivotal trial, a 64% relative increase in complete wound closure was seen in the Dermagraft-treated patients; 30.0% of Dermagraft and 18.3% of conventional therapy patients achieved complete wound closure at 12 weeks. The most frequently reported adverse events experienced by patients in the Dermagraft group (terms ≥ 5%) included infection, accidental injury, skin dysfunction/blister, flu syndrome, osteomyelitis, surgeries involving study ulcer, wound enlargement/skin ulcer, cellulitis and peripheral edema/localized swelling. These adverse events were similar to those seen in the control group.